231 related articles for article (PubMed ID: 25931171)
1. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.
Bellone S; Centritto F; Black J; Schwab C; English D; Cocco E; Lopez S; Bonazzoli E; Predolini F; Ferrari F; Silasi DA; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2015 Jul; 138(1):11-7. PubMed ID: 25931171
[TBL] [Abstract][Full Text] [Related]
2. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
Bellone S; Bignotti E; Lonardi S; Ferrari F; Centritto F; Masserdotti A; Pettinella F; Black J; Menderes G; Altwerger G; Hui P; Lopez S; de Haydu C; Bonazzoli E; Predolini F; Zammataro L; Cocco E; Ferrari F; Ravaggi A; Romani C; Facchetti F; Sartori E; Odicino FE; Silasi DA; Litkouhi B; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Jan; 144(1):146-152. PubMed ID: 27894751
[TBL] [Abstract][Full Text] [Related]
3. Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer.
Santin AD; Bellone S; Ravaggi A; Roman JJ; Pecorelli S; Parham GP; Cannon MJ
Br J Cancer; 2002 Jan; 86(1):151-7. PubMed ID: 11857027
[TBL] [Abstract][Full Text] [Related]
4. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
Santin AD; Bellone S; Palmieri M; Bossini B; Roman JJ; Cannon MJ; Bignotti E; Canè S; Pecorelli S
Gynecol Oncol; 2003 May; 89(2):271-80. PubMed ID: 12713991
[TBL] [Abstract][Full Text] [Related]
5. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
6. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
van Gool IC; Eggink FA; Freeman-Mills L; Stelloo E; Marchi E; de Bruyn M; Palles C; Nout RA; de Kroon CD; Osse EM; Klenerman P; Creutzberg CL; Tomlinson IP; Smit VT; Nijman HW; Bosse T; Church DN
Clin Cancer Res; 2015 Jul; 21(14):3347-3355. PubMed ID: 25878334
[TBL] [Abstract][Full Text] [Related]
7. The more tumors change, the more they stay tame: do T cells keep POLE ultramutated endometrial carcinomas in check?
Nelson BH; McAlpine JN
Gynecol Oncol; 2015 Jul; 138(1):1-2. PubMed ID: 26072691
[No Abstract] [Full Text] [Related]
8. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
9. In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells.
Kass R; Agha J; Bellone S; Palmieri M; Canè S; Bignotti E; Henry-Tillman R; Hutchins L; Cannon MJ; Klimberg S; Santin AD
J Surg Res; 2003 Jun; 112(2):189-97. PubMed ID: 12888337
[TBL] [Abstract][Full Text] [Related]
10. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH
Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557
[TBL] [Abstract][Full Text] [Related]
11. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract][Full Text] [Related]
12. POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction.
Li Y; Bian Y; Wang K; Wan XP
BMC Med Genet; 2019 Dec; 20(1):202. PubMed ID: 31864301
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
Baxevanis CN; Voutsas IF; Tsitsilonis OE; Gritzapis AD; Sotiriadou R; Papamichail M
J Immunol; 2000 Apr; 164(7):3902-12. PubMed ID: 10725753
[TBL] [Abstract][Full Text] [Related]
14. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.
Santin AD; Bellone S; Ravaggi A; Pecorelli S; Cannon MJ; Parham GP
Obstet Gynecol; 2000 Sep; 96(3):422-30. PubMed ID: 10960637
[TBL] [Abstract][Full Text] [Related]
15. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.
Kurokawa T; Oelke M; Mackensen A
Int J Cancer; 2001 Mar; 91(6):749-56. PubMed ID: 11275975
[TBL] [Abstract][Full Text] [Related]
16. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.
Herr W; Ranieri E; Olson W; Zarour H; Gesualdo L; Storkus WJ
Blood; 2000 Sep; 96(5):1857-64. PubMed ID: 10961887
[TBL] [Abstract][Full Text] [Related]
17. Phenotype of POLE-mutated endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Rau TT; Mueller MD; Epstein E; Carlson JW
PLoS One; 2019; 14(3):e0214318. PubMed ID: 30917185
[TBL] [Abstract][Full Text] [Related]
18. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma.
Raffone A; Travaglino A; Raimondo D; Boccellino MP; Maletta M; Borghese G; Casadio P; Insabato L; Mollo A; Zullo F; Seracchioli R
Gynecol Oncol; 2021 May; 161(2):621-628. PubMed ID: 33715893
[TBL] [Abstract][Full Text] [Related]
20. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.
Yamanaka R; Honma J; Tsuchiya N; Yajima N; Kobayashi T; Tanaka R
J Neurooncol; 2005 Apr; 72(2):107-13. PubMed ID: 15925989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]